查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1620470

2024 - 2032 年植入前基因检测 (PGT) 市场机会、成长动力、产业趋势分析与预测

Preimplantation Genetic Testing (PGT) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，全球胚胎植入前基因检测（PGT）市值为7.808亿美元，预计2024年至2032年复合年增长率为9.4%。不断增长推动的。 PGT 为家庭提供了一种在植入前检测胚胎遗传异常的主动选择，有助于预防遗传性疾病并提高整体生殖结果。市场按产品和服务类别细分​​。此产品领域包括 IVF 程序中使用的基本试剂、定序试剂盒和测试耗材，在 2023 年引领市场，预计 2024-2032 年复合年增长率为 9.3%。遗传性疾病发生率的增加，加上体外受精的广泛采用，增加了这些试剂盒和消耗品的需求。

新一代定序 (NGS) 等基因技术的最新进展推动了需求，并创造了更精确、更有效率的检测试剂盒。消耗品的经常性也确保了稳定的收入来源，突显了该部门的获利能力。从技术上讲，PGT市场包括NGS、萤光原位杂交（FISH）、聚合酶炼式反应（PCR）、基于阵列的方法等。由于其速度、准确性以及在一次测试中检测多种遗传异常的能力，NGS 到 2023 年将占据最大的市场份额，达到 42%。

该技术可以同时对多个胚胎进行测序，从而降低生育诊所和研究人员的成本并提高效率。随着精准筛检需求的不断增强，PGT 中 NGS 的采用不断增加，使其成为生殖遗传技术的领导者。从地区来看，2023 年美国在北美 PGT 市场占据主导地位，销售额为 3.122 亿美元，预计在预测期内将保持这一领先地位。该国广泛采用先进的生殖技术和强烈的基因筛检意识促成了这一优势。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 7.808 亿美元
预测值 17亿美元
复合年增长率 9.4%

此外，顶级生育诊所和尖端PGT供应商进一步巩固了美国在北美市场的地位。由于人们越来越关註生殖健康和基因筛检的进步，植入前基因检测市场将稳定成长。随着产品创新和高精度基因技术的广泛应用，PGT 市场仍然能够满足不断增长的人口寻求增强生殖选择的需求。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 遗传疾病发生率上升
      • 不孕不育率不断上升
      • PGT 技术不断进步
    • 产业陷阱与挑战
      • 基因检测费用高
      • PGT 方法的技术挑战
  • 成长潜力分析
  • 监管环境
  • 技术景观
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品和服务划分，2021 - 2032 年

  • 主要趋势
  • 产品
  • 服务

第 6 章：市场估计与预测：按技术分类，2021 - 2032 年

  • 主要趋势
  • 下一代定序（NGS）
  • 聚合酶炼式反应 (PCR)
  • 萤光原位杂交（FISH）
  • 大批
  • 其他技术

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 非整倍体筛检
  • 染色体结构重排
  • 单基因/单基因疾病筛检
  • 人类白血球抗原 (HLA) 分型
  • 其他应用

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院和诊所
  • 诊断实验室
  • 生育中心
  • 科学研究机构

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：公司简介

  • Agilent Technologies
  • Fulgent Genetics
  • Genea BIOMEDX
  • Illumina
  • Medicover Genetics
  • Natera
  • Revvity
  • RGI
  • Takara Bio
  • Thermo Fisher Scientific
  • Varinos
  • Virtus Health
  • Vitrolife Group (Igenomix)
简介目录
Product Code: 12034

The Global Preimplantation Genetic Testing (PGT) Market, valued at USD 780.8 million in 2023, is projected to grow at a CAGR of 9.4% from 2024 to 2032. This growth is driven by a rising awareness of reproductive health and a growing demand for genetic disorder screening in newborns. PGT provides families with a proactive option to detect genetic abnormalities in embryos before implantation, helping prevent hereditary conditions and enhancing overall reproductive outcomes. The market is segmented by product and service categories. The product segment, which includes essential reagents, sequencing kits, and testing consumables used in IVF procedures, led the market in 2023 and is expected to grow at a CAGR of 9.3% during 2024-2032. The increasing rate of genetic disorders, coupled with the expanding adoption of IVF, has heightened the demand for these kits and consumables.

Recent advancements in genetic technologies like next-generation sequencing (NGS) have driven demand and created more precise and efficient testing kits. The consumables' recurring nature also ensures a stable revenue stream, underscoring the profitability of this segment. Technologically, the PGT market includes NGS, fluorescent in-situ hybridization (FISH), polymerase chain reaction (PCR), array-based methods, and more. NGS holds the largest market share at 42% in 2023 due to its speed, accuracy, and ability to detect a wide range of genetic abnormalities in one test.

This technology can sequence multiple embryos simultaneously, reducing costs and increasing efficiency for fertility clinics and researchers. As the demand for precise screening intensifies, the adoption of NGS in PGT continues to rise, establishing it as a leader in reproductive genetic technology. Regionally, the U.S. dominated the North American PGT market in 2023, accounting for USD 312.2 million, and is expected to maintain this lead through the forecast period. The country's extensive adoption of advanced reproductive technologies and a strong awareness of genetic screening contribute to this dominance.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$780.8 Million
Forecast Value$1.7 Billion
CAGR9.4%

Moreover, top fertility clinics and cutting-edge PGT providers further solidify the U.S. position in the North American market. The preimplantation genetic testing market is set for steady growth due to the increasing focus on reproductive health and genetic screening advancements. With product innovations and the expanding utilization of high-precision genetic technologies, the PGT market remains poised to meet the needs of a growing demographic seeking enhanced reproductive options.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of genetic diseases
      • 3.2.1.2 Increasing prevalence of infertility rate
      • 3.2.1.3 Growing advancements in PGT technologies
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of genetic testing
      • 3.2.2.2 Technical challenges in PGT methods
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product & Service, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Products
  • 5.3 Services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Next generation sequencing (NGS)
  • 6.3 Polymerase chain reaction (PCR)
  • 6.4 Fluorescent in-situ hybridization (FISH)
  • 6.5 Array
  • 6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Aneuploidy screening
  • 7.3 Structural chromosomal rearrangement
  • 7.4 Monogenic/single-gene disorder screening
  • 7.5 Human leukocyte antigen (HLA) typing
  • 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals & clinics
  • 8.3 Diagnostic laboratories
  • 8.4 Fertility centers
  • 8.5 Research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Agilent Technologies
  • 10.2 Fulgent Genetics
  • 10.3 Genea BIOMEDX
  • 10.4 Illumina
  • 10.5 Medicover Genetics
  • 10.6 Natera
  • 10.7 Revvity
  • 10.8 RGI
  • 10.9 Takara Bio
  • 10.10 Thermo Fisher Scientific
  • 10.11 Varinos
  • 10.12 Virtus Health
  • 10.13 Vitrolife Group (Igenomix)